{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:05:48Z","timestamp":1791223548479,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.vaccine.2013.04.045","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T20:45:53Z","timestamp":1367527553000},"page":"2919-2929","source":"Crossref","is-referenced-by-count":49,"title":["Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD"],"prefix":"10.1016","volume":"31","author":[{"given":"Shannon J.","family":"Heine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovita","family":"Diaz-McNair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Martinez-Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamal P.","family":"Choudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy L.","family":"Picking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela F.","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9859","key":"10.1016\/j.vaccine.2013.04.045_bib0005","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"9859","key":"10.1016\/j.vaccine.2013.04.045_bib0010","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2013.04.045_bib0015","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/oxfordjournals.aje.a116134","article-title":"Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile","volume":"134","author":"Ferreccio","year":"1991","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.vaccine.2013.04.045_bib0020","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/JCM.29.2.386-389.1991","article-title":"Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis","volume":"29","author":"Cohen","year":"1991","journal-title":"J Clin Microbiol"},{"issue":"18","key":"10.1016\/j.vaccine.2013.04.045_bib0025","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1016\/j.vaccine.2005.07.014","article-title":"Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial","volume":"24","author":"McKenzie","year":"2006","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2013.04.045_bib0030","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1086\/424680","article-title":"Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208","volume":"190","author":"Kotloff","year":"2004","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2013.04.045_bib0035","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1128\/IAI.70.4.2016-2021.2002","article-title":"Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults","volume":"70","author":"Kotloff","year":"2002","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2013.04.045_bib0040","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.vaccine.2010.10.035","article-title":"Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh","volume":"29","author":"Rahman","year":"2011","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2013.04.045_bib0045","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1128\/IAI.64.10.4074-4077.1996","article-title":"Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers","volume":"64","author":"Cohen","year":"1996","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2013.04.045_bib0050","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1\u20134-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2013.04.045_bib0055","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.vaccine.2005.11.040","article-title":"Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine","volume":"24","author":"Oaks","year":"2006","journal-title":"Vaccine"},{"issue":"40","key":"10.1016\/j.vaccine.2013.04.045_bib0060","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2011.07.033","article-title":"Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine","volume":"29","author":"Riddle","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2013.04.045_bib0065","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrmicro1662","article-title":"Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road","volume":"5","author":"Levine","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2013.04.045_bib0070","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1586\/14760584.5.5.669","article-title":"Live-attenuated Shigella vaccines","volume":"5","author":"Venkatesan","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2013.04.045_bib0075","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1586\/erv.09.127","article-title":"Inactivated and subunit vaccines to prevent shigellosis","volume":"8","author":"Kaminski","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"10.1016\/j.vaccine.2013.04.045_bib0080","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/IAI.01599-06","article-title":"Bile salts stimulate recruitment of IpaB to the Shigella flexneri surface, where it colocalizes with IpaD at the tip of the type III secretion needle","volume":"75","author":"Olive","year":"2007","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2013.04.045_bib0085","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1128\/IAI.59.7.2341-2350.1991","article-title":"Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides","volume":"59","author":"Oberhelman","year":"1991","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2013.04.045_bib0090","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1128\/JCM.31.2.454-457.1993","article-title":"Immune response against lipopolysaccharide and invasion plasmid-coded antigens of shigellae in Vietnamese and Swedish dysenteric patients","volume":"31","author":"Cam","year":"1993","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2013.04.045_bib0095","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/infdis\/166.1.158","article-title":"Age-specific prevalence of serum antibodies to the invasion plasmid and lipopolysaccharide antigens of Shigella species in Chilean and North American populations","volume":"166","author":"Van de Verg","year":"1992","journal-title":"J Infect Dis"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2013.04.045_bib0100","first-page":"263","article-title":"Antibodies against invasion plasmid coded antigens of shigellae in human colostrum and milk","volume":"39","author":"Cam","year":"1992","journal-title":"Acta Microbiol Hung"},{"issue":"6","key":"10.1016\/j.vaccine.2013.04.045_bib0105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/hv.4746","article-title":"Safety and immunogenicity of CVD 1208S, a live, oral \u0394aguaBA \u0394sen \u0394set Shigella flexneri 2a vaccine grown on animal-free media","volume":"3","author":"Kotloff","year":"2007","journal-title":"Hum Vaccin"},{"issue":"4","key":"10.1016\/j.vaccine.2013.04.045_bib0110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.vaccine.2008.10.081","article-title":"Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates","volume":"27","author":"Simon","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2013.04.045_bib0115","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/IAI.06174-11","article-title":"Broadly protective Shigella vaccine based on type III secretion apparatus proteins","volume":"80","author":"Martinez-Becerra","year":"2012","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2013.04.045_bib0120","doi-asserted-by":"crossref","first-page":"e6999","DOI":"10.1371\/journal.pone.0006999","article-title":"Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin","volume":"4","author":"Lewis","year":"2009","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.vaccine.2013.04.045_bib0125","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2013.04.045_bib0130","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.vaccine.2009.10.147","article-title":"Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin","volume":"28","author":"Summerton","year":"2010","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2013.04.045_bib0135","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1128\/IAI.00440-06","article-title":"IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri","volume":"74","author":"Espina","year":"2006","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2013.04.045_bib0140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0003-2697(92)90279-G","article-title":"Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins","volume":"200","author":"Mach","year":"1992","journal-title":"Anal Biochem"},{"issue":"2","key":"10.1016\/j.vaccine.2013.04.045_bib0145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/mi.2009.131","article-title":"Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection","volume":"3","author":"Ramirez","year":"2010","journal-title":"Mucosal Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2013.04.045_bib0150","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/mi.2009.100","article-title":"Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa","volume":"2","author":"Khader","year":"2009","journal-title":"Mucosal Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2013.04.045_bib0155","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.4049\/jimmunol.0901838","article-title":"Secretory IgA-mediated neutralization of Shigella flexneri prevents intestinal tissue destruction by down-regulating inflammatory circuits","volume":"183","author":"Boullier","year":"2009","journal-title":"J Immunol"},{"issue":"15\u201316","key":"10.1016\/j.vaccine.2013.04.045_bib0160","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0264-410X(00)00433-3","article-title":"Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells","volume":"19","author":"Conway","year":"2001","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2013.04.045_bib0165","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/0264-410X(95)00016-T","article-title":"Human immune responses to influenza virus vaccines administered by systemic or mucosal routes","volume":"13","author":"Moldoveanu","year":"1995","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2013.04.045_bib0170","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.vaccine.2012.11.012","article-title":"Immune responses and protection in children in developing countries induced by oral vaccines","volume":"31","author":"Qadri","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2013.04.045_bib0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.all.0000225162.98391.81","article-title":"Oral tolerance and allergic responses to food proteins","volume":"6","author":"Strobel","year":"2006","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2013.04.045_bib0180","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-065X.2010.00970.x","article-title":"Immunology of gut mucosal vaccines","volume":"239","author":"Pasetti","year":"2011","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2013.04.045_bib0185","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/CVI.00036-10","article-title":"Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine","volume":"17","author":"Lu","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2013.04.045_bib0190","doi-asserted-by":"crossref","first-page":"e37722","DOI":"10.1371\/journal.pone.0037722","article-title":"Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine","volume":"7","author":"Remot","year":"2012","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.vaccine.2013.04.045_bib0195","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1128\/IAI.67.8.3970-3979.1999","article-title":"Thymic independence of adaptive immunity to the intracellular pathogen Shigella flexneri serotype 2a","volume":"67","author":"Way","year":"1999","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2013.04.045_bib0200","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0264-410X(94)00011-B","article-title":"Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli\u2013Shigella flexneri 2a vaccine strain EcSf2a-2","volume":"13","author":"Kotloff","year":"1995","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2013.04.045_bib0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/clinids\/15.2.346","article-title":"Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides","volume":"15","author":"Robbins","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2013.04.045_bib0210","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.4049\/jimmunol.136.3.1081","article-title":"Natural cytotoxic effector cell activity against Shigella flexneri-infected HeLa cells","volume":"136","author":"Klimpel","year":"1986","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2013.04.045_bib0215","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/gut.38.3.328","article-title":"Local entrapment of interferon gamma in the recovery from Shigella dysenteriae type 1 infection","volume":"38","author":"Raqib","year":"1996","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.vaccine.2013.04.045_bib0220","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1128\/IAI.65.12.5338-5341.1997","article-title":"A systemic downregulation of gamma interferon production is associated with acute shigellosis","volume":"65","author":"Raqib","year":"1997","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2013.04.045_bib0225","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1084\/jem.20111453","article-title":"IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells","volume":"209","author":"Coccia","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2013.04.045_bib0230","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2013.04.045_bib0235","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.4049\/jimmunol.0900978","article-title":"Th17 cells are the dominant T cell subtype primed by Shigella flexneri mediating protective immunity","volume":"184","author":"Sellge","year":"2010","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2013.04.045_bib0240","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1042\/bst0220295","article-title":"Shigella flexneri: from in vitro invasion of epithelial cells to infection of the intestinal barrier","volume":"22","author":"Sansonetti","year":"1994","journal-title":"Biochem Soc Trans"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13004970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13004970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:22:12Z","timestamp":1688214132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13004970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":48,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0264410X13004970"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.04.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}